|
Colorectal Carcinoma
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2.
|
19801554 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Upregulation of the TPX2 gene is associated with enhanced tumor malignance of esophageal squamous cell carcinoma.
|
23725757 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Inhibiting RelB in aggressive androgen-independent PC-3 cells by stable or conditional expression of a dominant-negative p100 mutant significantly reduced the incidence and growth rate of tumors.
|
19351823 |
2009 |
|
Primary malignant neoplasm
|
0.060 |
GeneticVariation
|
group |
BEFREE |
A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2.
|
19801554 |
2009 |
|
Malignant neoplasm of breast
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Following on these observations, we further assessed the link between the AURKA-HMMR-TPX2-TUBG1 functional module and risk of breast cancer in BRCA1 or BRCA2 mutation carriers.
|
25830658 |
2015 |
|
Breast Carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Following on these observations, we further assessed the link between the AURKA-HMMR-TPX2-TUBG1 functional module and risk of breast cancer in BRCA1 or BRCA2 mutation carriers.
|
25830658 |
2015 |
|
Multiple Myeloma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
C-terminal truncations of the NFKB2 p100 gene product have been observed in a number of cases of human cutaneous T cell lymphomas, as well as human B-cell lymphomas and myelomas.
|
10713675 |
2000 |
|
Malignant neoplasm of endometrium
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
EC: Endometrial cancer; 3'-UTR: 3'-untranslated regions; TPX2: target protein for Xenopus kinesin-like protein 2; TCGA: the Cancer Genome Atlas; UCEC: uterine corpus endometrial carcinoma; CCK-8: cell counting kit-8; OD: optical density; FCM: flow cytometry; EMT: epithelial-mesenchymal transition.
|
29888640 |
2018 |
|
Colitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Male rats were randomly assigned into four groups: sham, vehicle (with AAIC, treated with vehicle), P10 (with AAIC, treated with 10mg/kg HERP), and P100 (with AAIC, treated with 100mg/kg HERP).
|
27955827 |
2017 |
|
Lymphoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Assays of a series of additional lymphoma-associated NF-kappaB-2 truncation suggested that the C-terminal truncation associated with these proteins was also associated with a loss of the IkappaB-like activities of p100 NF-kappaB-2, for at least some NF-kappaB target promoters.
|
10713675 |
2000 |
|
Lymphoma, T-Cell, Cutaneous
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
C-terminal truncations of the NFKB2 p100 gene product have been observed in a number of cases of human cutaneous T cell lymphomas, as well as human B-cell lymphomas and myelomas.
|
10713675 |
2000 |
|
Visual symptoms
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Prolonged P100 peak latency of the visual evoked potentials (VEPs) were found in 16 patients (94.1%) in the early stage even without visual symptoms.
|
19473359 |
2009 |
|
Adult Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Assays of a series of additional lymphoma-associated NF-kappaB-2 truncation suggested that the C-terminal truncation associated with these proteins was also associated with a loss of the IkappaB-like activities of p100 NF-kappaB-2, for at least some NF-kappaB target promoters.
|
10713675 |
2000 |
|
Childhood Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Assays of a series of additional lymphoma-associated NF-kappaB-2 truncation suggested that the C-terminal truncation associated with these proteins was also associated with a loss of the IkappaB-like activities of p100 NF-kappaB-2, for at least some NF-kappaB target promoters.
|
10713675 |
2000 |
|
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells.
|
29606879 |
2018 |
|
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Totally, 427 upregulated (e.g., cell division cycle associated 5 [<i>CDCA5</i>], kinesin family member 4A [<i>KIF4A</i>], TPX2 microtubule nucleation factor [<i>TPX2</i>]) and 313 downregulated (e.g., metallothionein 1E [<i>MT1E</i>]) DEGs were identified in HCC.
|
31593490 |
2019 |
|
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
We finally extracted four genes, AKR1B10, HCAP-G, RRM2, and TPX2, as candidate therapeutic targets for HCC. siRNA-mediated knockdown of these candidate genes inhibited the proliferation of HCC cells and the growth of HCC xenografts transplanted into immunodeficient mice.
|
20388846 |
2010 |
|
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Colorectal Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Additionally, combined high expression of MYC, AURKA and TPX2 proved to be a poor prognostic indicator of colorectal cancer patient survival.
|
25632068 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpressed in cancers, TPX2 is being established as marker for the diagnosis and prognosis of malignancies.
|
24556998 |
2014 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of targeting protein for Xklp2 (TPX2) has been identified in numerous malignant tumors.
|
29620263 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The targeting protein for Xklp2 (TPX2) is a microtubule- and, cell cycle-associated protein who's overexpression has been reported in various malignancies.
|
25914189 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Partial degradation of the p100 subunit to generate p52 subunit is a hallmark of the alternative NF-κB pathway, which has been implicated in cancer.
|
26112410 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The targeting protein for Xklp2 (TPX2) has recently gained attention as a putative oncogene possibly amplified in several human malignancies, including pancreatic adenocarcinoma.
|
19861455 |
2009 |